You can buy or sell RFL and other stocks, options, ETFs, and crypto commission-free!
Rafael Holdings, Inc. owns commercial real estate assets and interests in clinical and early stage pharmaceutical companies. It operates through the Real Estate and Pharmaceuticals segments. Read More The Real Estate segment refers to the real estate holdings, including the building at 520 Broad Street in Newark, New Jersey that houses and the company's associated public garage, an office or data center building in Piscataway, New Jersey, and a portion of a building in Israel that hosts offices for IDT and certain affiliates. The Pharmaceuticals segment is comprised of debt interests and warrants in Rafael Pharmaceuticals and a majority equity interest in LipoMedix Pharmaceuticals, research and development, and clinical trials. The company is headquartered in Newark, NJ.
Newark, New Jersey
52 Week High
52 Week Low
Research And Development
PR NewswireMar 12
Rafael Holdings Reports Second Quarter Fiscal Year 2019 Results
NEWARK, N.J., March 12, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.0 million and a loss per share of $0.08 for the second quarter of its 2019 fiscal year, the three months ended January 31, 2019. Highlights Rafael Holdings exercised a warrant and now holds a majority of the outstanding equity of Rafael Pharmaceuticals, Inc., (Rafael Pharma), a clinical stage, metabolic oncology-therapeutics company; Rafael Pharma announced that the European Medicines Agency h...
-$0.08 per share